Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040

被引：0
|
作者：
Sangro, Bruno [1 ,2 ]
He, Aiwu Ruth [3 ]
Yau, Thomas [4 ]
Hsu, Chiun [5 ]
Kang, Yoon-Koo [6 ,7 ]
Kim, Tae-You [8 ]
Santoro, Armando [9 ]
Melero, Ignacio [10 ]
Kudo, Masatoshi [11 ]
Ho, Ming-Mo [12 ]
Matilla, Ana [13 ,14 ]
Tovoli, Francesco [15 ]
Knox, Jennifer [16 ]
El-Rayes, Bassel [17 ]
Acosta, Mirelis Rivera [18 ]
Neely, Jaclyn [19 ]
Shen, Yun [19 ]
Tschaika, Marina [19 ]
El-Khoureiry, Anthony [20 ]
机构：
[1] Clin Univ Navarra, Pamplona, Spain
[2] CIBEREHD, Pamplona, Spain
[3] Georgetown Univ Hosp, Washington, DC 20007 USA
[4] Univ Hong Kong, Hong Kong, Peoples R China
[5] Natl Taiwan Univ Hosp, Taipei, Taiwan
[6] Asan Med Ctr, Seoul, South Korea
[7] Univ Ulsan, Seoul, South Korea
[8] Seoul Natl Univ, Seoul, South Korea
[9] Ist Clin Humanitas, Rozzano, Italy
[10] Univ Navarra, Pamplona, Spain
[11] Kindai Univ, Fac Med, Osaka, Japan
[12] Chang Gung Mem Hosp, Taipei, Taiwan
[13] Hosp Gen Univ Gregorio Maranon, Serv Digest, Madrid, Spain
[14] CIBEREHD, Madrid, Spain
[15] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[16] Princess Margaret Canc Ctr, Toronto, ON, Canada
[17] Emory Univ, Winship Ctr, Atlanta, GA 30322 USA
[18] Fdn Invest, San Juan, PR USA
[19] Bristol Myers Squibb, Princeton, NJ USA
[20] USC, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LBO11
引用
收藏
页码：S121 / S122
页数：2
相关论文
共 50 条
  • [21] First-line nivolumab plus ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
    O'Byrne, K. J.
    Lee, K. H.
    Kim, S-W
    Park, K.
    Nishio, M.
    Sakai, H.
    Ohe, Y.
    Fukuhara, T.
    Kang, J-H
    Daga, H.
    Yu, C-J
    Hotta, K.
    Tanaka, H.
    Takeda, M.
    Yokoyama, T.
    Nathan, F. E.
    Lee, J-S
    ESMO OPEN, 2022, 7 (01)
  • [22] Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040
    Melero, Ignacio
    Neely, Jaclyn
    Sangro, Bruno
    Finn, Richard
    Abou-Alfa, Ghassan K.
    Cheng, Ann-Lii
    Yau, Thomas
    Furuse, Junji
    Park, Joong-Won
    Wadhawan, Samir
    Tang, Hao
    Delacruz, Christine
    Baccan, Carlos
    Boyd, Zach
    El-Khoueiry, Anthony
    CANCER RESEARCH, 2019, 79 (13)
  • [23] Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
    Emamekhoo, Hamid
    Olsen, Mark R.
    Carthon, Bradley C.
    Drakaki, Alexandra
    Percent, Ivor J.
    Molina, Ana M.
    Cho, Daniel C.
    Bendell, Johanna C.
    Gordan, Lucio N.
    Kalebasty, Arash Rezazadeh
    George, Daniel J.
    Hutson, Thomas E.
    Arrowsmith, Edward R.
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Leung, David K.
    Tykodi, Scott S.
    CANCER, 2022, 128 (05) : 966 - 974
  • [24] Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma
    Su, Y.
    Lin, Y.
    Hsiao, C.
    Ou, D.
    Chen, S.
    Wu, Y.
    Lee, W.
    Lin, J.
    Hsu, C.
    Ho, M.
    Lu, L.
    Wu, T.
    Lai, S.
    Chao, Y.
    Chou, T.
    Yen, C.
    Chen, L.
    Shan, Y.
    Cheng, A.
    Hsu, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S141 - S141
  • [25] Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study
    Sangro, B.
    Yau, T.
    Hsu, C.
    Kudo, M.
    Crocenzi, T. S.
    Choo, S. -P.
    Meyer, T.
    Welling, T. H., III
    Yeo, W.
    Chopra, A.
    Baakili, A.
    Dela Cruz, C.
    Lang, L.
    Neely, J.
    Melero, I.
    El-Khoueiry, A. B.
    Trojan, J.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S34 - S35
  • [26] Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study
    Ignacio, Melero
    Anthony, El-Khoueiry
    Thomas, Yau
    Chiun, Hsu
    Masatoshi, Kudo
    Todd, Crocenzi
    Tae-You, Kim
    Su-Pin, Choo
    Joerg, Trojan
    Theodore, Welling
    Yoon-Koo, Kang
    Winnie, Yeo
    Akhil, Chopra
    Adyb, Baakili
    Christine, dela Cruz
    Zhao Huanyu
    Bruno, Sangro
    Tim, Meyer
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040
    Sangro, Bruno
    Matilla, Ana M.
    Santoro, Armando
    Melero, Ignacio
    Cubillo Gracian, Antonio
    Rivera Acosta, Mirelis
    Choo, Su-Pin
    El-Khoureiry, Anthony
    Kuromatsu, Ryoko
    El-Rayes, Bassel
    Numata, Kazushi
    Itoh, Yoshito
    Di Costanzo, Francesco
    Crysler, Oxana
    Reig, Maria
    Shen, Yun
    Neely, Jaclyn
    Dela Cruz, Christine
    Baccan, Carlos
    Kudo, Masatoshi
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E619 - E619
  • [28] Nivolumab plus Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
    Tsang, Josephine
    Wong, Jeffrey Sum Lung
    Kwok, Gerry Gin Wai
    Li, Bryan Cho Wing
    Leung, Roland
    Chiu, Joanne
    Cheung, Tan to
    Yau, Thomas
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (06) : 589 - 598
  • [29] PKPD relationship of ipilimumab plus nivolumab combination in patients with advanced melanoma
    Goldwirt, L.
    Louveau, B.
    Liv, T.
    Baroudjian, B.
    Allayous, C.
    Da Meda, L.
    Delyon, J.
    Sauvageon, H.
    Lebbe, C.
    Mourah, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 38 - 38
  • [30] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345